Hims & Hers Health, INC Form 4 insider transactions

Director Christiane Pendarvis reports the vesting of 19,707 Restricted Stock Units (RSUs) convertible to Class A Common Stock on June 6, 2024, resulting in a total direct ownership of 30,917 Class A Common Stock shares.

Chief Medical Officer of Hims & Hers Health, Patrick Harrison Carroll, reports the vesting and acquisition of 19,707 Class A Common Stock units on June 6, 2024, increasing his direct holdings to 193,587 shares.

Director Ambar Bhattacharyya reported the vesting of 19,707 shares of Class A Common Stock and Restricted Stock Units (RSUs) on June 6, 2024.

Hims & Hers Health CFO Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Director Alex Bard reports vesting of Restricted Stock Units (RSUs) convertible to Class A Common Stock.

CEO Andrew Dudum exercised stock options and sold shares of Hims & Hers Health, Inc. on June 4, 2024, according to a Form 4 filing with the SEC.

Melissa Baird, COO of Hims & Hers Health, executed stock options and sold Class A Common Stock between June 3rd and June 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc., exercised stock options and sold shares of Class A Common Stock between May 31, 2024, and June 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,502 shares of Class A Common Stock at a price of $17.33 per share on May 28, 2024, under a pre-arranged trading plan.

Oluyemi Okupe, CFO of Hims & Hers Health, executed stock option exercises and sales of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Director Christopher Payne purchased 110,000 shares of Hims & Hers Health, Inc. at an average price of $17.7433 on May 21, 2024.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Irene Becklund, PAO of Hims & Hers Health, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Director Christiane Pendarvis of Hims & Hers Health, Inc. sold 4,000 shares of Class A Common Stock at a price of $12.33 on May 13, 2024.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,503 shares of Class A Common Stock at a price of $12.33 on May 13, 2024.

Patrick Harrison Carroll, Chief Medical Officer and Director of Hims & Hers Health, Inc., sold 10,000 shares of Class A Common Stock for $13 per share on May 9, 2024.

Director Anja Manuel reports acquisition of 30,120 Restricted Stock Units in Hims & Hers Health, Inc. with vesting over a three-year period.

Director Christopher D. Payne acquired 30,120 restricted stock units in Hims & Hers Health, Inc., subject to a three-year vesting schedule.

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares on May 1, 2024, according to a Form 4 filing with the SEC.

Hims & Hers Health's Chief Operating Officer, Melissa Baird, exercised stock options and sold shares of Class A Common Stock between May 1 and May 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,503 shares of Class A Common Stock at a price of $12.56 per share on April 29, 2024, under a pre-arranged 10b5-1 trading plan.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,503 shares of Class A Common Stock at $13.95 per share on April 15, 2024, under a pre-arranged 10b5-1 trading plan.

Hims & Hers Health's Chief Operating Officer, Melissa Baird, executed stock option exercises and sales of Class A Common Stock between April 4th and April 8th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on April 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,503 shares of Class A Common Stock at a price of $15.65 per share on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Andrew Dudum, CEO of Hims & Hers Health, sold 50,361 shares of Class A Common Stock on March 20, 2024, at an average price of $16.3431.

Hims & Hers Health CFO Oluyemi Okupe sold 9,912 shares of Class A Common Stock on March 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Irene Becklund, PAO of Hims & Hers Health, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units, including transactions related to tax obligations and a pre-arranged trading plan.

Director Lynne Chou O'Keefe reports converting Restricted Stock Units (RSUs) into Class A Common Stock and selling shares of Hims & Hers Health, Inc. under a pre-arranged Rule 10b5-1 trading plan.